Zelnorm, a drug prescribed for the short-term treatment of chronic constipation in irritable bowel syndrome (IBS) patients, was voluntarily withdrawn from the market on March 30, 2007. The U.S. Food & Drug Administration (FDA) requested that Novartis Pharmaceuticals, the maker of Zelnorm, remove the drug after a link to increased risks of stroke and heart attacks had been found.
However, the FDA later approved its market return with tighter restrictions to treat IBS with constipation and chronic idiopathic constipation (CIC) in women younger than 55. If you have taken Zelnorm and suffered a serious, adverse cardiovascular event, the Jacoby & Meyers defective drug attorneys can help you pursue damages.
Obtaining a successful resolution in a defective drug case, such as Zelnorm, takes an experienced attorney who will investigate, evaluate, and pursue claims that involve personal injury litigation. Navigating medical terminology, researching the various studies and developing a full understanding of the side effects is required for those seeking compensation.
Zelnorm Side Effects
Zelnorm was prescribed to move stools through the bowels in patients with irritable bowel syndrome. However, in treating the constipation associated with IBS, patients were exposed to other side effects including:
- Abdominal pain
- Dizziness and headache
- Intestinal gas
- Rectal bleeding
- Heart attack
Why Consider Bringing a Zelnorm Case?
Companies that make and distribute pharmaceutical drugs are charged with providing products that are safe and effective for the public. When those obligations are not met, a company can be held legally responsible for injuries that occur to patients. By pursuing damages related to your injury, you not only can potentially recover compensation for your pain and suffering, but you also put the responsible parties on notice that the general public demands safe products.
Please contact our defective drug lawyers today to schedule your free initial consultation. Jacoby & Meyers has offices throughout the U.S.